$ARQT earnings report

Arcutis reported third-quarter net product revenue of $143.9 million, up 45% year over year and 11% sequentially, raised 2026 net product sales guidance to $535 million–$545 million, and generated $18.9 million of operating cash flow. AlphAI read Arcutis Biotherapeutics's Third Quarter 2026 filing as strong.

Third Quarter 2026

AlphAI · Earnings readARQT · Third Quarter 2026 · ended September 30, 2026

Arcutis reported third-quarter net product revenue of $143.9 million, up 45% year over year and 11% sequentially, raised 2026 net product sales guidance to $535 million–$545 million, and generated $18.9 million of operating cash flow.

✓Strong quarter

Product revenue growth, positive GAAP net income, positive operating cash flow, and a higher full-year net product sales outlook were accompanied by materially higher SG&A spending to support marketing and sales-force expansion.

Revenue
144M
ZORYVE cream 0.3%
$37.8M
EPS · GAAP
$ 0.06
Full year 2026 outlook
$535 million–$545 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net, three months ended September 30, 2026GAAP$143.9M11%45%
Other revenue, three months ended September 30, 2026GAAP—––
Total revenues, three months ended September 30, 2026GAAP143.9M––
Cost of sales, three months ended September 30, 2026GAAP12.46M––
Research and development, three months ended September 30, 2026GAAP22.42M––
Selling, general, and administrative, three months ended September 30, 2026GAAP99.60M––
Total operating expenses, three months ended September 30, 2026GAAP134.5M––
Income from operations, three months ended September 30, 2026GAAP9.44M––
Interest income, three months ended September 30, 2026GAAP2.60M––
Interest expense, three months ended September 30, 2026GAAP−2.96M––
Other income (expense), net, three months ended September 30, 2026GAAP−77K––
Total other income (expense), three months ended September 30, 2026GAAP−440K––
Income before income taxes, three months ended September 30, 2026GAAP9.00M––
Provision for income taxes, three months ended September 30, 2026GAAP195K––
Net income, three months ended September 30, 2026GAAP$8.80M––
Basic earnings per share, three months ended September 30, 2026GAAP$ 0.07––
Diluted earnings per share, three months ended September 30, 2026GAAP$ 0.06––
Weighted-average shares used in computing basic earnings per share, three months ended September 30, 2026GAAP131.0M––
Weighted-average shares used in computing diluted earnings per share, three months ended September 30, 2026GAAP136.8M––
Product revenue, net, nine months ended September 30, 2026GAAP$379.2M––
Other revenue, nine months ended September 30, 2026GAAP—––
Total revenues, nine months ended September 30, 2026GAAP379.2M––
Cost of sales, nine months ended September 30, 2026GAAP33.18M––
Research and development, nine months ended September 30, 2026GAAP73.40M––
Selling, general, and administrative, nine months ended September 30, 2026GAAP255.8M––
Total operating expenses, nine months ended September 30, 2026GAAP362.4M––
Income (loss) from operations, nine months ended September 30, 2026GAAP16.78M––
Interest income, nine months ended September 30, 2026GAAP7.15M––
Interest expense, nine months ended September 30, 2026GAAP−10.73M––
Other income (expense), net, nine months ended September 30, 2026GAAP−254K––
Total other income (expense), nine months ended September 30, 2026GAAP−3.84M––
Income (loss) before income taxes, nine months ended September 30, 2026GAAP12.94M––
Provision for income taxes, nine months ended September 30, 2026GAAP424K––
Net income (loss), nine months ended September 30, 2026GAAP$12.52M––
Basic earnings (loss) per share, nine months ended September 30, 2026GAAP$ 0.10––
Diluted earnings (loss) per share, nine months ended September 30, 2026GAAP$ 0.09––
Weighted-average shares used in computing basic earnings (loss) per share, nine months ended September 30, 2026GAAP130.3M––
Weighted-average shares used in computing diluted earnings (loss) per share, nine months ended September 30, 2026GAAP136.2M––
Cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026GAAP$259.8M––
Cash and cash equivalents as of September 30, 2026GAAP$33.37M––
Restricted cash as of September 30, 2026GAAP308K––
Marketable securities as of September 30, 2026GAAP226.1M––
Current portion of long-term debt, net, as of September 30, 2026GAAP6.95M––
Long-term debt, net, as of September 30, 2026GAAP102.4M––
Net cash provided by operating activities, third quarter of 2026GAAP$18.9M––

Segments

SegmentRevenueq/qy/y
ZORYVE cream 0.3%All products grew in the quarter; increases were predominantly due to increased unit demand and modest improvements in gross-to-net deductions.$37.8M––
ZORYVE cream 0.15%All products grew in the quarter; increases were predominantly due to increased unit demand and modest improvements in gross-to-net deductions.$27.3M––
ZORYVE cream 0.05%All products grew in the quarter; increases were predominantly due to increased unit demand and modest improvements in gross-to-net deductions.$3.7M––
ZORYVE topical foam 0.3%All products grew in the quarter; increases were predominantly due to increased unit demand and modest improvements in gross-to-net deductions.$75.1M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$535 million–$545 million
  • NoteNet product sales guidance was raised from $525 million–$540 million.
  • NoteThe FDA target action date for the supplemental New Drug Application for ZORYVE cream 0.05% is February 23, 2027.
  • NoteThe Company expects to report hidradenitis suppurativa Phase 2 results, as well as a decision on program advancement, in the first quarter of 2027.
  • NoteThe Company remains on track to disclose topline Phase 2 vitiligo results and its program-advancement decision by the end of 2026.

What drove it

  • ZORYVE net product sales growth was driven by increasing demand across products.
  • Year-over-year and quarter-over-quarter product revenue increases were predominantly due to increased unit demand and modest improvements in gross-to-net deductions.
  • R&D expense increased primarily because of ARQ-234 clinical development expense and medical-affairs investment supporting education on roflumilast programs.
  • SG&A expense increased due to marketing for the Skin to Believe In celebrity awareness campaign and personnel-related costs from dermatology sales-force expansion and the launch of the primary care provider and pediatric sales team.

Concerns

  • SG&A expense was 99,601 (in thousands) in the third quarter of 2026, compared to 62,404 (in thousands) in the corresponding 2025 period.
  • R&D expense was 22,422 (in thousands) in the third quarter of 2026, compared to 19,604 (in thousands) in the corresponding 2025 period.
  • Interest expense was (10,733) (in thousands) for the nine months ended September 30, 2026, compared to (9,082) (in thousands) in the corresponding 2025 period.
  • The filing identifies clinical development, regulatory approval, commercialization, future commercial sales, gross-to-net deductions, reimbursement, and intellectual-property risks.

What to watch

  • FDA action on the supplemental New Drug Application for ZORYVE cream 0.05% for infants aged 3 to 24 months, with a target action date of February 23, 2027.
  • Topline results and program-advancement decision for ZORYVE foam 0.3% in vitiligo by the end of 2026.
  • Phase 2 hidradenitis suppurativa results and program-advancement decision expected in the first quarter of 2027.
  • Enrollment and advancement of the Phase 3 trial of ZORYVE cream 0.3% in moderate to severe atopic dermatitis and the Phase 1a/1b ARQ-234 trial.

Balance sheet and cash flow

  • Cash, cash equivalents, restricted cash, and marketable securities were $259.8 million as of September 30, 2026, compared to $221.3 million as of December 31, 2025.
  • Net cash provided by operating activities was $18.9 million during the third quarter.
  • Trade receivables, net were 171,281 (in thousands) as of September 30, 2026, compared to 146,229 (in thousands) as of December 31, 2025.
  • Inventory was 45,669 (in thousands) as of September 30, 2026, compared to 22,634 (in thousands) as of December 31, 2025.
  • Long-term debt, net was 102,448 (in thousands) as of September 30, 2026, compared to 107,959 (in thousands) as of December 31, 2025.

Analysis

Arcutis delivered a strong commercial quarter. Net product revenue was $143.9 million, up 45% versus the corresponding 2025 period and up 11% versus the second quarter of 2026. The company attributed the year-over-year and sequential growth to increased demand across products and modest improvements in gross-to-net deductions. ZORYVE topical foam 0.3% generated $75.1 million of quarterly revenue, while ZORYVE cream 0.3%, cream 0.15%, and cream 0.05% generated $37.8 million, $27.3 million, and $3.7 million, respectively.

The company remained profitable on a GAAP basis, reporting net income of $8,801 (in thousands), or $0.06 diluted earnings per share, compared with net income of $7,410 (in thousands), or $0.06 diluted earnings per share, in the corresponding 2025 quarter. Income from operations was 9,436 (in thousands), compared with 8,526 (in thousands). For the nine-month period, the company reported net income of $12,515 (in thousands), compared with a net loss of $(33,536) (in thousands) a year earlier, while income from operations was 16,776 (in thousands), compared with an operating loss of (30,614) (in thousands).

Cost growth reflected commercial scale-up and pipeline investment. Cost of sales rose to 12,460 (in thousands) from 8,685 (in thousands) with higher ZORYVE sales volume. R&D increased to 22,422 (in thousands) from 19,604 (in thousands), driven primarily by ARQ-234 clinical development and medical-affairs spending. SG&A rose to 99,601 (in thousands) from 62,404 (in thousands), reflecting marketing for the Skin to Believe In campaign, dermatology sales-force expansion, and launch of the primary care provider and pediatric sales team.

Cash generation remained positive, with $18.9 million of net cash provided by operating activities during the third quarter. Cash, cash equivalents, restricted cash, and marketable securities were $259.8 million as of September 30, 2026, compared with $221.3 million as of December 31, 2025. The company raised full-year 2026 net product sales guidance to $535 million–$545 million from $525 million–$540 million, reinforcing management's reported demand outlook.

The next operating milestones are clinical and regulatory. The FDA has set February 23, 2027 as the target action date for the supplemental application for ZORYVE cream 0.05% in infants aged 3 to 24 months. Arcutis also expects to disclose vitiligo Phase 2 topline results and a program-advancement decision by the end of 2026, followed by hidradenitis suppurativa Phase 2 results and an advancement decision in the first quarter of 2027.

Management, verbatim

Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations. We are very excited to launch a new awareness campaign with Simone Biles, a World Champion gymnast who uses ZORYVE herself, to raise awareness of inflammatory skin diseases and of advanced targeted topicals like ZORYVE.

Frank Watanabe, president and chief executive officer

Looking ahead, with a potential FDA approval of ZORYVE cream 0.05% for infants as young as 3 months in the first quarter of 2027, the progress of our indication expansion trials, and the advancement of our ARQ-234 Phase 1 trial, we are well positioned to drive continued growth.

Frank Watanabe, president and chief executive officer

Not in the filing

stated, not guessed
  • Gross margin and prior-year gross margin were not reported.
  • Non-GAAP financial measures were not reported.
  • Free cash flow was not reported.
  • Cash flow from investing activities and financing activities were not reported.
  • Share repurchases, dividends, and other capital-return activity were not reported.
  • Total debt was not presented as a single line item.
  • Prior-quarter values for the income statement line items were not reported.
  • A prior outlook section was not provided; therefore, no comparison of actual results against prior guidance is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ARQT earnings dates

When is Arcutis Biotherapeutics's next earnings date?
AlphAI has no date for ARQT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.